BioCryst Pharmaceuticals Inc.

05/12/2021 | Press release | Distributed by Public on 05/12/2021 07:26

BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients